EFFICIENCY AND SAFETY OF EXOSOMES TREATMENT IN SARS-COV-2 CAUSED INFECTIOUS DISEASES
doi.org/10.17721/1728.2748.2025.100.15-25
Keywords:
SARS-CoV-2, COVID-19, exosomes, mesenchymal stem (stromal) cells, clinical trialsAbstract
Coronavirus disease (COVID-19) is a severe acute respiratory disease caused by the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need for reliable therapy to combat the clinical complications caused by the SARS-CoV-2 virus. Exosomes are vesicles that play a role in intercellular communication. Exosomes are paracrine and endocrine mediators that contain chemokines, growth factors, mRNAs and microRNAs with anti-inflammatory, regenerative and immunomodulatory functions. Exosomes may be a pleiotropic therapeutic agent in the fight against SARS-CoV-2 infection. In this work, we analyzed current studies, including clinical trials those investigate exosomes COVID-19 intervention. The most studies aim is to test the safety and efficacy of drugs. Exosomes obtained from different sources have many common characteristics, but they can also differ in functionality. The majority of trials have focused on the study of exosomes derived from MSCs, the sources of which are placenta, umbilical cord, amniotic fluid, adipose tissue and bone marrow. In addition, exosomes can be used as carriers of CD24-enriched drugs, and can be obtained from other sources, such as virus-specific T cells. The non-targeted exosomes delivery method to the human body may be the reason for the low efficiency of exosomes application. Nebulized delivery of exosomes may be new targeted delivery method instead of intravenous administration. Although the data are still insufficient for the widespread use of exosomes treatment of coronavirus disease, it is already possible to determine the current state of art, production, delivery methods and the main groups of researchers and companies working on this topic.
References
Alahdal M, Elkord E. (2022) Promising use of immune cell-derived exosomes in the treatment of SARS-CoV-2 infections. Clin Transl Med. 2022 Aug;12(8):e1026. doi: 10.1002/ctm2.1026. PMID: 35988156; PMCID: PMC9393056.
ClinicalTrials.gov. National Library of Medicine (US). Accessed 2024 Dec 07. Available from: https://clinicaltrials.gov/search?cond=Covid19&term=Exosomes
cochranelibrary.com Accessed 2024 Dec 07. Available from https://www.cochranelibrary.com/search
Galipeau J, Sensébé L. (2018) Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. PMID: 29859173; PMCID: PMC6434696.
García LF. (2020) Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020 Jun 16;11:1441. doi: 10.3389/fimmu.2020.01441. PMID: 32612615; PMCID: PMC7308593.
Grigoropoulos I, Tsioulos G, Kastrissianakis A, Shapira S, Green O, Rapti V, Tsakona M, Konstantinos T, Savva A, Kavatha D, Boumpas D, Syrigos K, Xynogalas I, Leontis K, Ntousopoulos V, Sakka V, Sardelis Z, Fotiadis A, Vlassi L, Kontogianni C, Levounets A, Poulakou G, Gaga M, MacLoughlin R, Stebbing J, Arber N, Antoniadou A, Tsiodras S. (2024) The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS. Respir Res. 2024 Apr 1;25(1):151. doi: 10.1186/s12931-024-02759-5. PMID: 38561798; PMCID: PMC10983648.
Heldring N, Mäger I, Wood MJA, Le Blanc K, Andaloussi SEL. (2015) Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Hum Gene Ther. 2015;26(8):506–17
Hessvik NP, Llorente A. (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018 Jan;75(2):193-208. doi: 10.1007/s00018-017-2595-9. Epub 2017 Jul 21. PMID: 28733901; PMCID: PMC5756260.
Hu B, Guo H, Zhou P, Shi ZL. (2022) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-154. doi: 10.1038/s41579-020-00459-7. Epub 2020 Oct 6. Erratum in: Nat Rev Microbiol. 2022 May;20(5):315. doi: 10.1038/s41579-022-00711-2. PMID: 33024307; PMCID: PMC7537588.
Jamalkhah, M., Asaadi, Y., Azangou-Khyavy, M. et al. (2021) MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak. J Transl Med 19, 164 (2021). https://doi.org/10.1186/s12967-021-02840-3Д
Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, et al. (2013) Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54(5):1293–6.
Kanvinde S, Deodhar S, Kulkarni TA, Jogdeo CM. (2023) Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis. BioTech (Basel). 2023 May 5;12(2):34. doi: 10.3390/biotech12020034. PMID: 37218751; PMCID: PMC10204512.
Karlton T. Watson (2022) Warning Letter #OBPO 22-627699 FDA July 28, 2022 (https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vitti-labs-llc-627699-07282022 )
Lightner, Amy L. et al. (2023) Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19 CHEST, Volume 164, Issue 6, 1444 – 1453 https://doi.org/10.1016/j.chest.2023.06.024
Lim SK, Giebel B, Weiss DJ, Witwer KW, Rohde E. (2020) Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al. Stem Cells Dev. 2020 Jul;29(14):877-878. doi: 10.1089/scd.2020.0089. Epub 2020 Jun 10. PMID: 32520641; PMCID: PMC7374615.
Lotfy, A., AboQuella, N.M. & Wang, H. (2023) Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther 14, 66 (2023). https://doi.org/10.1186/s13287-023-03287-7
Mitrani MI, Bellio MA, Meglin A, Khan A, Xu X, Haskell G, Arango A, Shapiro GC. (2021) Treatment of a COVID-19 long hauler with an amniotic fluid-derived extracellular vesicle biologic. Respir Med Case Rep. 2021;34:101502. doi: 10.1016/j.rmcr.2021.101502. Epub 2021 Aug 30. PMID: 34485048; PMCID: PMC8405236.
Mitrani MI, Bellio MA, Sagel A, Saylor M, Kapp W, VanOsdol K, Haskell G, Stewart D, Abdullah Z, Santos I, Milberg J, Arango A, Mitrani A and Shapiro GC (2021) Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients. Front. Med. 8:583842. doi: 10.3389/fmed.2021.583842
Mori, T.; Giovannelli, L.; Bilia, A.R.; Margheri, F. (2023) Exosomes: Potential Next-Generation Nanocarriers for the Therapy of Inflammatory Diseases. Pharmaceutics 2023, 15, 2276. https://doi.org/10.3390/pharmaceutics15092276
PR Newswire (2021) Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers PR Newswire July 22, 2021 https://exosome-rna.com/organicell-announces-fda-approval-of-ind-application-for-the-use-of-zofin-in-covid-19-long-haulers/
PRNewswire, Press Releases (2019) Direct Biologics Announces the Launch of ExoFlo Exosomes July 12, 2019 https://exosome-rna.com/direct-biologics-announces-the-launch-of-exoflo-exosomes/
Raza, S., Seth, P., & Khan, M. (2020). ‘Primed’ Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients. Stem Cell Reviews And Reports. doi: 10.1007/s12015-020-09999-0
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N.(2020) Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. doi: 10.1089/scd.2020.0080. Epub 2020 May 12. PMID: 32380908; PMCID: PMC7310206.
Shapira S, Ben Shimon M, Hay-Levi M, Shenberg G, Choshen G, Bannon L, Tepper M, Kazanov D, Seni J, Lev-Ari S, Peer M, Boubas D, Stebbing J, Tsiodras S, Arber N. (2022) A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond. EMBO Mol Med. 2022 Sep 7;14(9):e15997. doi: 10.15252/emmm.202215997. Epub 2022 Jul 13. PMID: 35776000; PMCID: PMC9349550.
Shapira S, Kazanov D, Weisblatt S, Starr A, Arber N, Kraus S. (2011) The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo. J Biol Chem. 2011 Nov 25;286(47):40548-55. doi: 10.1074/jbc.M111.286534. Epub 2011 Oct 5. PMID: 21976680; PMCID: PMC3220457.
Shi MM, Yang QY, Monsel A, Yan JY, Dai CX, Zhao JY, Shi GC, Zhou M, Zhu XM, Li SK, Li P, Wang J, Li M, Lei JG, Xu D, Zhu YG, Qu JM. (2021) Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021 Aug;10(10):e12134. doi: 10.1002/jev2.12134. Epub 2021 Aug 14. PMID: 34429860; PMCID: PMC8363910.
Tang Y, Zhou Y, Li HJ. (2021) Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021 Jan 19;12(1):71. doi: 10.1186/s13287-021-02138-7. PMID: 33468232; PMCID: PMC7814175.
Théry C, Witwer KW, Aikawa E, et al. (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. PMID: 30637094; PMCID: PMC6322352.
Urtė Fultinavičiūtė (2023) Direct Biologics’ ExoFlo shows decreased mortality in Covid-19 patients Clinical trials Arena July 13, 2023 https://www.clinicaltrialsarena.com/news/direct-biologics-exoflo-covid-19/?cf-view
Vikram Sengupta, Sascha Sengupta, Angel Lazo, Jr., Kevin C. Hicok, and Timothy Moseley Response to Kim et al. (2020) re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19” STEM CELLS AND DEVELOPMENT Volume 29, Number 14, 2020 DOI: 10.1089/scd.2020.0095
Wiklander OP, Nordin JZ, O'Loughlin A, Gustafsson Y, Corso G, et al. (2015) Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015 Apr 20;4:26316. doi: 10.3402/jev.v4.26316. PMID: 25899407; PMCID: PMC4405624.
Ye Q, Wang B, Mao J. (2020) The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. PMID: 32283152; PMCID: PMC7194613
Zhu YG, Shi MM, Monsel A, Dai CX, Dong X, Shen H, Li SK, Chang J, Xu CL, Li P, Wang J, Shen MP, Ren CJ, Chen DC, Qu JM. (2022) Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther. 2022 May 26;13(1):220. doi: 10.1186/s13287-022-02900-5. PMID: 35619189; PMCID: PMC9135389
